GLP-1-based therapies have fundamentally transformed the treatment of obesity and type 2 diabetes. But research is already taking it a step further: Prof. Timo Müller, Director of the Institute for Diabetes and Obesity (IDO) at Helmholtz Munich, discusses polyagonists and innovative hybrid molecules that target multiple metabolic pathways simultaneously and release active components precisely to its destination.
Read the full interview on the Helmholtz Munich website:
Interview with Timo Müller on new therapies for obesity and diabetes.
